Cargando…
Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918596/ https://www.ncbi.nlm.nih.gov/pubmed/35287234 http://dx.doi.org/10.1007/s12325-022-02082-9 |
| _version_ | 1784668764206268416 |
|---|---|
| author | Schreiber, Stefan Ben-Horin, Shomron Alten, Rieke Westhovens, René Peyrin-Biroulet, Laurent Danese, Silvio Hibi, Toshifumi Takeuchi, Ken Magro, Fernando An, Yoorim Kim, Dong-Hyeon Yoon, SangWook Reinisch, Walter |
| author_facet | Schreiber, Stefan Ben-Horin, Shomron Alten, Rieke Westhovens, René Peyrin-Biroulet, Laurent Danese, Silvio Hibi, Toshifumi Takeuchi, Ken Magro, Fernando An, Yoorim Kim, Dong-Hyeon Yoon, SangWook Reinisch, Walter |
| author_sort | Schreiber, Stefan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8918596 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer Healthcare |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89185962022-03-14 Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era Schreiber, Stefan Ben-Horin, Shomron Alten, Rieke Westhovens, René Peyrin-Biroulet, Laurent Danese, Silvio Hibi, Toshifumi Takeuchi, Ken Magro, Fernando An, Yoorim Kim, Dong-Hyeon Yoon, SangWook Reinisch, Walter Adv Ther Correction Springer Healthcare 2022-03-14 2022 /pmc/articles/PMC8918596/ /pubmed/35287234 http://dx.doi.org/10.1007/s12325-022-02082-9 Text en © Springer Healthcare Ltd., part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Correction Schreiber, Stefan Ben-Horin, Shomron Alten, Rieke Westhovens, René Peyrin-Biroulet, Laurent Danese, Silvio Hibi, Toshifumi Takeuchi, Ken Magro, Fernando An, Yoorim Kim, Dong-Hyeon Yoon, SangWook Reinisch, Walter Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era |
| title | Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era |
| title_full | Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era |
| title_fullStr | Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era |
| title_full_unstemmed | Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era |
| title_short | Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era |
| title_sort | correction to: perspectives on subcutaneous infliximab for rheumatic diseases and inflammatory bowel disease: before, during, and after the covid-19 era |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918596/ https://www.ncbi.nlm.nih.gov/pubmed/35287234 http://dx.doi.org/10.1007/s12325-022-02082-9 |
| work_keys_str_mv | AT schreiberstefan correctiontoperspectivesonsubcutaneousinfliximabforrheumaticdiseasesandinflammatoryboweldiseasebeforeduringandafterthecovid19era AT benhorinshomron correctiontoperspectivesonsubcutaneousinfliximabforrheumaticdiseasesandinflammatoryboweldiseasebeforeduringandafterthecovid19era AT altenrieke correctiontoperspectivesonsubcutaneousinfliximabforrheumaticdiseasesandinflammatoryboweldiseasebeforeduringandafterthecovid19era AT westhovensrene correctiontoperspectivesonsubcutaneousinfliximabforrheumaticdiseasesandinflammatoryboweldiseasebeforeduringandafterthecovid19era AT peyrinbirouletlaurent correctiontoperspectivesonsubcutaneousinfliximabforrheumaticdiseasesandinflammatoryboweldiseasebeforeduringandafterthecovid19era AT danesesilvio correctiontoperspectivesonsubcutaneousinfliximabforrheumaticdiseasesandinflammatoryboweldiseasebeforeduringandafterthecovid19era AT hibitoshifumi correctiontoperspectivesonsubcutaneousinfliximabforrheumaticdiseasesandinflammatoryboweldiseasebeforeduringandafterthecovid19era AT takeuchiken correctiontoperspectivesonsubcutaneousinfliximabforrheumaticdiseasesandinflammatoryboweldiseasebeforeduringandafterthecovid19era AT magrofernando correctiontoperspectivesonsubcutaneousinfliximabforrheumaticdiseasesandinflammatoryboweldiseasebeforeduringandafterthecovid19era AT anyoorim correctiontoperspectivesonsubcutaneousinfliximabforrheumaticdiseasesandinflammatoryboweldiseasebeforeduringandafterthecovid19era AT kimdonghyeon correctiontoperspectivesonsubcutaneousinfliximabforrheumaticdiseasesandinflammatoryboweldiseasebeforeduringandafterthecovid19era AT yoonsangwook correctiontoperspectivesonsubcutaneousinfliximabforrheumaticdiseasesandinflammatoryboweldiseasebeforeduringandafterthecovid19era AT reinischwalter correctiontoperspectivesonsubcutaneousinfliximabforrheumaticdiseasesandinflammatoryboweldiseasebeforeduringandafterthecovid19era |